Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.66 HKD
−423.16 M HKD
792.19 M HKD
81.61 M
About BIOCYTOGEN PHARMACEUTICALS (BEIJING
Sector
CEO
Yue Lei Shen
Website
Headquarters
Beijing
Founded
2009
ISIN
CNE100005D27
FIGI
BBG01998SR48
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. It operates through the following segments: Gene Editing Services, Pre-Clinical Pharmacology and Efficacy Evaluation, Animal Models Selling, Antibody Development, and Innovative Drugs Development. The Gene Editing Services segment provides gene editing services. The Pre-Clinical Pharmacology and Efficacy Evaluation segment involves in the provision of pre-clinical pharmacology service for drug efficacy and toxicity evaluation. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment includes one-stop solution from antibody preparation to IND filing for the customer. The Innovative Drugs Development consists of research and developing drugs with a focus on oncology and autoimmune disease therapeutics. The company was founded by Yue Lei Shen on November 13, 2009 and is headquartered in Beijing, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2315 is 6.00 HKD — it hasn't changed in the past 24 hours. Watch BIOCYTOGEN PHARMACEUTICALS (BEIJING stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange BIOCYTOGEN PHARMACEUTICALS (BEIJING stocks are traded under the ticker 2315.
2315 stock has risen by 3.45% compared to the previous week, the month change is a −17.81% fall, over the last year BIOCYTOGEN PHARMACEUTICALS (BEIJING has showed a −54.41% decrease.
We've gathered analysts' opinions on BIOCYTOGEN PHARMACEUTICALS (BEIJING future price: according to them, 2315 price has a max estimate of 13.23 HKD and a min estimate of 13.23 HKD. Watch 2315 chart and read a more detailed BIOCYTOGEN PHARMACEUTICALS (BEIJING stock forecast: see what analysts think of BIOCYTOGEN PHARMACEUTICALS (BEIJING and suggest that you do with its stocks.
2315 reached its all-time high on Oct 19, 2022 with the price of 28.80 HKD, and its all-time low was 5.60 HKD and was reached on Nov 14, 2024. View more price dynamics on 2315 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
2315 stock is 10.75% volatile and has beta coefficient of 1.28. Track BIOCYTOGEN PHARMACEUTICALS (BEIJING stock price on the chart and check out the list of the most volatile stocks — is BIOCYTOGEN PHARMACEUTICALS (BEIJING there?
Today BIOCYTOGEN PHARMACEUTICALS (BEIJING has the market capitalization of 2.39 B, it has increased by 7.14% over the last week.
Yes, you can track BIOCYTOGEN PHARMACEUTICALS (BEIJING financials in yearly and quarterly reports right on TradingView.
BIOCYTOGEN PHARMACEUTICALS (BEIJING is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
2315 earnings for the last half-year are −0.14 HKD per share, whereas the estimation was −0.13 HKD, resulting in a −8.33% surprise. The estimated earnings for the next half-year are 0.01 HKD per share. See more details about BIOCYTOGEN PHARMACEUTICALS (BEIJING earnings.
BIOCYTOGEN PHARMACEUTICALS (BEIJING revenue for the last half-year amounts to 441.05 M HKD, despite the estimated figure of 440.74 M HKD. In the next half-year revenue is expected to reach 576.36 M HKD.
2315 net income for the last half-year is −54.91 M HKD, while the previous report showed −208.66 M HKD of net income which accounts for 73.68% change. Track more BIOCYTOGEN PHARMACEUTICALS (BEIJING financial stats to get the full picture.
No, 2315 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 1.07 K employees. See our rating of the largest employees — is BIOCYTOGEN PHARMACEUTICALS (BEIJING on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOCYTOGEN PHARMACEUTICALS (BEIJING EBITDA is 35.20 M HKD, and current EBITDA margin is −17.78%. See more stats in BIOCYTOGEN PHARMACEUTICALS (BEIJING financial statements.
Like other stocks, 2315 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOCYTOGEN PHARMACEUTICALS (BEIJING stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOCYTOGEN PHARMACEUTICALS (BEIJING technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOCYTOGEN PHARMACEUTICALS (BEIJING stock shows the sell signal. See more of BIOCYTOGEN PHARMACEUTICALS (BEIJING technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.